A team of researchers have determined the structure of a protein, which is considered to be the possible target for the development of drugs to treat diabetes.
The researchers have discovered the three-dimensional structure of a protein MitoNEET, which was previously identified as a spot where diabetes drugs could operate.
The discovery makes it possible to design small molecules that interact with it and modify its function. The researchers say that MitoNEET has a novel three-dimensional structure that makes it a particularly interesting candidate for the design of innovative compounds that can bind to it.
This is the first time that a protein like this has ever been found, said Patricia Jennings, a professor in UCSDs department of Chemistry and Biochemistry who led the study along with Mark Paddock, a project scientist in UCSDs Physics department.
It is a brand new structure, a unique beast, which makes it an exciting target for structure-based drug design. We are grateful about the highly collaborative spirit of the UCSD community that brought such diverse expertise and helped us tackle such a complex project, Jennings added.
Our work may provide a basis for the design of newer diabetes drugs that have potentially greater specificity and fewer side effects than existing ones, added Paddock.
Following the initial work of co-authors Sandra Wiley, Anne Murphy and Jack Dixon at UCSDs School of Medicine, and in collaboration with Herbert Axelrod and Aina Cohen at the Stanford Synchrotron Radiation Laboratory and Rachel Nechushtai at the Hebrew University of Jerusalem, also co-authors on the paper, the team determined that mitoNEET is an iron-sulphur protein.